Last reviewed · How we verify

Perineural Dexamethasone and bupivacaine

Sherif Mohamed Abd el moneim Soaida, MD · FDA-approved active Small molecule

Perineural dexamethasone and bupivacaine combination provides local anesthesia and reduces inflammation at the nerve injection site to prolong anesthetic duration and reduce postoperative pain.

Perineural dexamethasone and bupivacaine combination provides local anesthesia and reduces inflammation at the nerve injection site to prolong anesthetic duration and reduce postoperative pain. Used for Peripheral nerve blocks for surgical anesthesia and postoperative pain management, Regional anesthesia adjuvant therapy.

At a glance

Generic namePerineural Dexamethasone and bupivacaine
SponsorSherif Mohamed Abd el moneim Soaida, MD
Drug classLocal anesthetic with adjuvant corticosteroid
TargetVoltage-gated sodium channels (bupivacaine); glucocorticoid receptor (dexamethasone)
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhaseFDA-approved

Mechanism of action

Bupivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing pain signal transmission. Dexamethasone, a corticosteroid, is added to the perineural injection to reduce local inflammation and potentially extend the duration of the nerve block by decreasing nerve inflammation and improving local tissue conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results